ProMIS Neurosciences, Inc. Q3 2026 Earnings Call Summary
ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
ProMIS Neurosciences Q3 EPS $(0.89) Beats $(1.28) Estimate
ProMIS Neurosciences to Participate in Upcoming Conferences in November
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
Roth Capital Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $15
Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ...
Promis Neurosciences Q2 Earnings Call Highlights
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript
ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69
Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study
ProMIS Neurosciences Shares Climb on Positive Interim Alzheimer’s Trial Safety Results
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.